Lilly, Boehringer Win U.S. Approval for Type 2 Diabetes Drug
Eli Lilly & Co. (LLY) and Boehringer Ingelheim GmbH won U.S. approval of a new drug to improve blood glucose control in people with Type 2 diabetes.
The drug, linagliptin, was shown to be safe and effective in eight clinical studies involving about 3,800 patients with Type 2 diabetes, the most common form of the disease, the Food and Drug Administration said today in a statement.
To contact the reporter on this story: Molly Peterson in Washington at email@example.com
To contact the editor responsible for this story: Adriel Bettelheim at firstname.lastname@example.org.